A 57-year-old male presents with a primary complaint of erectile dysfunction. After proper evaluation, the patient is started on daily administration of sildenafil. This medication directly causes accumulation of which of the following intracellular mediators?
Q912
A 75-year-old female patient comes to the emergency department with altered mental status. She is brought in by her daughter with whom the patient lives. The patient’s daughter said they were watching TV when her mother became unresponsive. On exam the patient withdraws to pain but does not open her eyes or speak. An emergent head CT is done and shows an intracranial bleed. The patient is moved to the ICU and intubated. Further history is obtained from the daughter. The patient has a past medical history of diabetes and a previous stroke. Her medications are metformin and warfarin. The patient is compliant with all of her medications. The daughter says that the patient changed her diet about 1 month ago in response to a diet she saw on a talk show. Which of the following foods is most likely to cause the pathology seen in this patient?
Q913
A 72-year-old woman is brought to the emergency department because of increasing abdominal pain for 6 hours. The pain is dull and diffuse over her abdomen and radiates to her lower back bilaterally. Three weeks ago, she was diagnosed with atrial fibrillation and started on warfarin. Her only other medication is 1 g of acetaminophen daily for osteoarthritis of her knees. Her pulse is 87/min and blood pressure is 112/75 mm Hg. Physical examination shows abdominal tenderness to palpation at both lower quadrants. A CT scan of the abdomen shows a retroperitoneal mass and hazy margins of the surrounding structures. In addition to discontinuation of warfarin, the most appropriate next step in management is administration of which of the following?
Q914
A 26-year-old woman, gravida 2, para 1, at 26 weeks’ gestation, comes to the emergency department because of pain and swelling in her right calf. Physical examination shows an increased circumference of the right calf. The leg is warm and tender on palpation. Dorsiflexion of the right foot elicits calf pain. An ultrasound of the right leg shows a noncompressible popliteal vein. Which of the following is the most appropriate pharmacotherapy for this patient's condition?
Q915
A 36-year-old man presents to a psychiatrist for management of nicotine dependence. He has been a heavy smoker for the past 20 years. He has unsuccessfully attempted to quit smoking many times. He has seen multiple physicians for nicotine dependence. They prescribed nicotine replacement therapy and varenicline. He has also taken two antidepressants and participated in talk therapy. He asks the psychiatrist whether there are other alternatives. The psychiatrist explains that nicotine replacement therapy, non-nicotine pharmacotherapy, and talk therapy are the best options for the management of nicotine dependence. He tells the patient he can take a second-line medication for non-nicotine pharmacotherapy because the first-line medication failed. Which of the following medications would the psychiatrist most likely use to manage this patient’s nicotine dependence?
Q916
A 27-year-old woman develops progressive difficulty breathing after a long day of chores in a dusty house. These chores included brushing the family dog, vacuuming, dusting, and sweeping. She occasionally gets these episodes once or twice a year and has her medication on hand. Her symptoms are reversed by inhaling a β2-adrenergic receptor agonist. Which of the following chemical mediators is responsible for this patient’s breathing difficulties?
Q917
A 65-year-old man comes to the physician because of a 2-week history of chest pain that begins after walking at a brisk pace for 2 blocks. The pain does not radiate anywhere and is hard to localize. He has had similar episodes in the past 6 months and was prescribed sublingual nitroglycerin, which helps relieve the pain. The patient has hypertension and type 2 diabetes mellitus. He takes lisinopril and metformin daily. He appears well. His temperature is 37°C (98.6°F), pulse is 75/min, and blood pressure is 145/90 mm Hg. Examination shows a regular heart rhythm. S1 and S2 are normal. The lungs are clear to auscultation. There is no peripheral edema. Which of the following is the most likely explanation for the improvement of this patient's chest pain?
Q918
A 55-year-old male is started on nitrate therapy for treatment of stable angina. He experiences significant and immediate relief of his symptoms within minutes of starting therapy. Approximately 48 hours after initiating this new medication, he notes return of chest pain and pressure with exertion that no longer responds to continued nitrate use. Which of the following 24-hour dosing schedules would most likely explain this patient's response to nitrate treatment?
Q919
A 51-year-old male presents to his primary care provider for a normal check-up. He reports that he “hasn’t felt like himself” recently. He describes feeling down for the past 8 months since his mother passed away. He has had trouble sleeping and has unintentionally lost 15 pounds. He feels guilty about his mother’s death but cannot articulate why. His performance at work has declined and he has stopped running, an activity he used to enjoy. He has not thought about hurting himself or others. Of note, he also complains of numbness in his feet and fingers and inability to maintain an erection. His past medical history is notable for diabetes. He is on metformin. His temperature is 98.6°F (37°C), blood pressure is 125/65 mmHg, pulse is 90/min, and respirations are 16/min. On exam, he is alert and oriented with intact memory and normal speech. He appears tired with a somewhat flattened affect. The best medication for this patient inhibits which of the following processes?
Q920
Ten days after starting a new medication, a 60-year-old man is brought to the emergency department after a 3-minute episode of myoclonic jerking movements and urinary incontinence. After regaining consciousness, the patient had no recollection of what happened and seemed confused. He has bipolar disorder, which has been controlled with maintenance therapy for the past 15 years. Physical examination shows dry oral mucosa, muscle fasciculations, and bilateral hand tremors. His speech is slow, and he is disoriented. Which of the following drugs most likely precipitated this patient's current condition?
Autonomic/CV Drugs US Medical PG Practice Questions and MCQs
Question 911: A 57-year-old male presents with a primary complaint of erectile dysfunction. After proper evaluation, the patient is started on daily administration of sildenafil. This medication directly causes accumulation of which of the following intracellular mediators?
A. Ca2+
B. AMP
C. cGMP (Correct Answer)
D. NO
E. ANP
Explanation: ***cGMP***
- Sildenafil is a **phosphodiesterase-5 (PDE5) inhibitor** which prevents the degradation of **cyclic guanosine monophosphate (cGMP)**.
- Accumulation of cGMP leads to **smooth muscle relaxation** and increased blood flow, which is crucial for achieving an erection.
*Ca2+*
- **Calcium ions (Ca2+)** are essential for muscle contraction, and a decrease in intracellular Ca2+ generally promotes relaxation, which is the opposite effect desired for PDE5 inhibitors.
- Sildenafil's mechanism does not directly increase intracellular Ca2+; rather, it indirectly promotes relaxation by a cGMP-mediated pathway that reduces Ca2+ sensitivity or levels.
*AMP*
- **Adenosine monophosphate (AMP)** is a product of ATP hydrolysis and is involved in cellular energy metabolism, but it is not directly accumulated by sildenafil.
- The pathway targeted by sildenafil involves guanylate cyclase and phosphodiesterase, not directly affecting AMP levels in this context.
*NO*
- **Nitric oxide (NO)** is a crucial signaling molecule that activates guanylate cyclase, leading to cGMP production. Sildenafil does not directly cause accumulation of NO; instead, it potentiates the effects of NO by preventing cGMP degradation.
- NO is the upstream mediator that triggers the cGMP pathway, and its presence is necessary for sildenafil to be effective.
*ANP*
- **Atrial natriuretic peptide (ANP)** is a hormone primarily involved in blood pressure regulation and fluid balance, often leading to natriuresis and vasodilation.
- While ANP also acts through a cGMP pathway, sildenafil specifically targets PDE5, which primarily breaks down cGMP generated in response to NO, not ANP.
Question 912: A 75-year-old female patient comes to the emergency department with altered mental status. She is brought in by her daughter with whom the patient lives. The patient’s daughter said they were watching TV when her mother became unresponsive. On exam the patient withdraws to pain but does not open her eyes or speak. An emergent head CT is done and shows an intracranial bleed. The patient is moved to the ICU and intubated. Further history is obtained from the daughter. The patient has a past medical history of diabetes and a previous stroke. Her medications are metformin and warfarin. The patient is compliant with all of her medications. The daughter says that the patient changed her diet about 1 month ago in response to a diet she saw on a talk show. Which of the following foods is most likely to cause the pathology seen in this patient?
A. Grapefruit juice (Correct Answer)
B. St. John’s wort
C. Green tea
D. Chili peppers
E. Spinach
Explanation: ***Grapefruit juice***
- **Grapefruit juice** is a potent inhibitor of **cytochrome P450 3A4 (CYP3A4)**, which is involved in the metabolism of **warfarin**.
- Inhibition of warfarin metabolism leads to increased warfarin levels, subsequently potentiating its **anticoagulant effect** and significantly increasing the risk of **bleeding**, including dangerous **intracranial hemorrhage**.
*St. John’s wort*
- **St. John's wort** is a known **CYP3A4 inducer**, meaning it increases the metabolism of drugs like warfarin.
- This typically leads to **decreased warfarin efficacy** and thus an increased risk of **thrombosis**, not bleeding.
*Green tea*
- **Green tea** contains **vitamin K**, which can **antagonize the effects of warfarin**.
- Ingesting large amounts of green tea could potentially *reduce* warfarin's anticoagulant effect, increasing the risk of clotting, rather than bleeding.
*Chili peppers*
- **Chili peppers** do not have a well-documented significant interaction with **warfarin** that would lead to increased bleeding risk.
- Their primary effects relate to gastric irritation or altered sensation, not anticoagulant modulation.
*Spinach*
- **Spinach** is high in **vitamin K**, which is a crucial factor in blood clotting and is directly antagonized by **warfarin**.
- Increased intake of spinach would likely **decrease the efficacy of warfarin**, leading to a higher risk of **clotting**, not bleeding.
Question 913: A 72-year-old woman is brought to the emergency department because of increasing abdominal pain for 6 hours. The pain is dull and diffuse over her abdomen and radiates to her lower back bilaterally. Three weeks ago, she was diagnosed with atrial fibrillation and started on warfarin. Her only other medication is 1 g of acetaminophen daily for osteoarthritis of her knees. Her pulse is 87/min and blood pressure is 112/75 mm Hg. Physical examination shows abdominal tenderness to palpation at both lower quadrants. A CT scan of the abdomen shows a retroperitoneal mass and hazy margins of the surrounding structures. In addition to discontinuation of warfarin, the most appropriate next step in management is administration of which of the following?
A. Aminocaproic acid and packed red blood cells
B. Phytonadione and prothrombin complex concentrate (Correct Answer)
C. Fresh frozen plasma and tranexamic acid
D. Factor VIII and von Willebrand factor
E. Protamine sulfate and hydroxyethyl starch
Explanation: ***Phytonadione and prothrombin complex concentrate***
- This patient presents with signs of **retroperitoneal hemorrhage** while on **warfarin**, indicated by abdominal pain radiating to the back and a retroperitoneal mass on CT.
- **Phytonadione (Vitamin K)** reverses warfarin's effects by promoting the synthesis of clotting factors, while **prothrombin complex concentrate (PCC)** provides immediate replacement of these factors, crucial for rapid hemostasis in serious bleeding.
*Aminocaproic acid and packed red blood cells*
- **Aminocaproic acid** is an antifibrinolytic and is not the primary intervention for warfarin-induced bleeding, which requires urgent reversal of anticoagulation.
- **Packed red blood cells** are used for volume resuscitation and to correct anemia but do not address the underlying coagulopathy caused by warfarin.
*Fresh frozen plasma and tranexamic acid*
- While **fresh frozen plasma (FFP)** contains clotting factors and can reverse warfarin effects, **PCC** is generally preferred for its faster action and smaller volume, especially in hemorrhaging patients.
- **Tranexamic acid** is an antifibrinolytic and is not the first-line treatment for warfarin-induced bleeding, which requires direct reversal of anticoagulation.
*Factor VIII and von Willebrand factor*
- **Factor VIII** and **von Willebrand factor** are treatments for specific bleeding disorders like hemophilia A or von Willebrand disease, respectively.
- They are not indicated for reversing the effects of warfarin, which inhibits synthesis of vitamin K-dependent factors (II, VII, IX, X).
*Protamine sulfate and hydroxyethyl starch*
- **Protamine sulfate** is used to reverse the effects of **heparin** (unfractionated and low molecular weight), not warfarin.
- **Hydroxyethyl starch** is a plasma volume expander, used for fluid resuscitation, but does not correct coagulopathy.
Question 914: A 26-year-old woman, gravida 2, para 1, at 26 weeks’ gestation, comes to the emergency department because of pain and swelling in her right calf. Physical examination shows an increased circumference of the right calf. The leg is warm and tender on palpation. Dorsiflexion of the right foot elicits calf pain. An ultrasound of the right leg shows a noncompressible popliteal vein. Which of the following is the most appropriate pharmacotherapy for this patient's condition?
A. Warfarin
B. Heparin (Correct Answer)
C. Aspirin
D. Clopidogrel
E. Rivaroxaban
Explanation: ***Heparin***
- The patient presents with symptoms and ultrasound findings consistent with a **deep vein thrombosis (DVT)** in pregnancy. **Heparin** (specifically **low molecular weight heparin** or **unfractionated heparin**) is the anticoagulant of choice during pregnancy because it does not cross the placenta.
- It works by activating **antithrombin III**, which inhibits various clotting factors, primarily **Factor Xa** and **thrombin (Factor IIa)**, thus preventing further clot propagation.
*Warfarin*
- **Warfarin** is a **teratogen** and is absolutely **contraindicated in pregnancy**, especially during the first trimester and near term, due to its association with **fetal warfarin syndrome** (chondrodysplasia punctata) and risk of fetal hemorrhage.
- It is an **oral anticoagulant** that inhibits vitamin K-dependent clotting factors (**II, VII, IX, X**).
*Aspirin*
- **Aspirin** is an **antiplatelet agent** that inhibits **COX-1**, reducing **thromboxane A2** production and platelet aggregation.
- While it has a role in preventing preeclampsia, it is **not sufficient for treating an acute DVT** in pregnancy, which requires full anticoagulation.
*Clopidogrel*
- **Clopidogrel** is an **antiplatelet agent** that inhibits the **P2Y12 ADP receptor** on platelets, preventing platelet activation and aggregation.
- Similar to aspirin, it is effective in arterial thrombosis but is **not the primary treatment for venous thromboembolism (VTE)** like DVT in pregnancy.
*Rivaroxaban*
- **Rivaroxaban** is a **direct oral anticoagulant (DOAC)** that directly inhibits **Factor Xa**.
- **DOACs** are generally **not recommended for use in pregnancy** due to limited safety data and concerns about placental transfer, making heparin the preferred choice.
Question 915: A 36-year-old man presents to a psychiatrist for management of nicotine dependence. He has been a heavy smoker for the past 20 years. He has unsuccessfully attempted to quit smoking many times. He has seen multiple physicians for nicotine dependence. They prescribed nicotine replacement therapy and varenicline. He has also taken two antidepressants and participated in talk therapy. He asks the psychiatrist whether there are other alternatives. The psychiatrist explains that nicotine replacement therapy, non-nicotine pharmacotherapy, and talk therapy are the best options for the management of nicotine dependence. He tells the patient he can take a second-line medication for non-nicotine pharmacotherapy because the first-line medication failed. Which of the following medications would the psychiatrist most likely use to manage this patient’s nicotine dependence?
A. Topiramate
B. Methadone
C. Clonidine (Correct Answer)
D. Buprenorphine
E. Lorazepam
Explanation: ***Clonidine***
- **Clonidine** is a **second-line agent** for smoking cessation, particularly effective for managing **withdrawal symptoms** like anxiety, irritability, and restlessness.
- It works as an **alpha-2 adrenergic agonist**, reducing sympathetic outflow and alleviating the somatic symptoms of nicotine withdrawal.
*Topiramate*
- **Topiramate** is an anticonvulsant sometimes used off-label for **alcohol dependence** or **weight management**; it is not a primary or secondary treatment for nicotine dependence.
- Its mechanism of action involves GABAergic and glutamatergic modulation, which is not directly targeted at nicotine withdrawal.
*Methadone*
- **Methadone** is an **opioid agonist** primarily used in the treatment of **opioid use disorder** to prevent withdrawal symptoms and reduce cravings.
- It has no established role in the direct management of nicotine dependence or smoking cessation.
*Buprenorphine*
- **Buprenorphine** is a **partial opioid agonist** used in the treatment of **opioid use disorder**, often combined with naloxone.
- Similar to methadone, it is not indicated for the treatment of nicotine dependence.
*Lorazepam*
- **Lorazepam** is a **benzodiazepine** used to treat **anxiety, insomnia**, and **seizures** due to its sedative and anxiolytic properties.
- While it could help with anxiety associated with nicotine withdrawal, it is not a direct treatment for nicotine dependence and carries risks of dependence itself.
Question 916: A 27-year-old woman develops progressive difficulty breathing after a long day of chores in a dusty house. These chores included brushing the family dog, vacuuming, dusting, and sweeping. She occasionally gets these episodes once or twice a year and has her medication on hand. Her symptoms are reversed by inhaling a β2-adrenergic receptor agonist. Which of the following chemical mediators is responsible for this patient’s breathing difficulties?
A. Histamine
B. Leukotrienes (Correct Answer)
C. Serotonin
D. Bradykinin
E. Endorphins
Explanation: ***Correct: Leukotrienes***
- Leukotrienes, particularly **leukotriene C4, D4, and E4**, are potent **bronchoconstrictors** and are significantly involved in the pathogenesis of **asthma**.
- They also contribute to **bronchial hyperreactivity**, mucus secretion, and airway edema, all hallmarks of asthmatic exacerbations triggered by allergens and irritants.
*Incorrect: Histamine*
- Histamine is released by mast cells and basophils, causing **bronchoconstriction** and vasodilation, but its role in the **sustained and severe bronchospasm of asthma** is less prominent than leukotrienes.
- While it contributes to immediate hypersensitivity reactions, **antihistamines are generally not effective in treating asthma exacerbations**.
*Incorrect: Serotonin*
- Serotonin (5-hydroxytryptamine) is primarily involved in smooth muscle contraction and platelet aggregation, but it is **not a primary mediator of bronchoconstriction in human asthma**.
- Its effects on the airways are relatively minor compared to other mediators.
*Incorrect: Bradykinin*
- Bradykinin is a peptide that causes **vasodilation**, increased vascular permeability, and pain, and can induce **bronchoconstriction**, especially in sensitive individuals.
- However, it is **not considered a primary or dominant mediator in typical allergic asthma exacerbations** as described in this patient.
*Incorrect: Endorphins*
- Endorphins are **endogenous opioid peptides** that primarily act as **neurotransmitters** and neuromodulators, involved in pain sensation and mood regulation.
- They have **no direct role in the acute pathophysiology of asthma** or bronchoconstriction.
Question 917: A 65-year-old man comes to the physician because of a 2-week history of chest pain that begins after walking at a brisk pace for 2 blocks. The pain does not radiate anywhere and is hard to localize. He has had similar episodes in the past 6 months and was prescribed sublingual nitroglycerin, which helps relieve the pain. The patient has hypertension and type 2 diabetes mellitus. He takes lisinopril and metformin daily. He appears well. His temperature is 37°C (98.6°F), pulse is 75/min, and blood pressure is 145/90 mm Hg. Examination shows a regular heart rhythm. S1 and S2 are normal. The lungs are clear to auscultation. There is no peripheral edema. Which of the following is the most likely explanation for the improvement of this patient's chest pain?
A. Delayed electrical conduction
B. Increased atherosclerotic plaque stability
C. Coronary arterial vasodilation
D. Decreased end-diastolic pressure (Correct Answer)
E. Decreased venous pooling
Explanation: ***Decreased end-diastolic pressure***
- Sublingual **nitroglycerin is a potent vasodilator** that primarily acts on the venous system, leading to venous pooling and reduced venous return to the heart.
- This reduction in **preload** (end-diastolic pressure/volume) decreases myocardial oxygen demand, which alleviates exertional angina.
*Coronary arterial vasodilation*
- While nitroglycerin does cause some **coronary artery vasodilation**, especially in areas of stenosis, its primary mechanism for relieving angina is through the reduction of **preload**, which reduces myocardial oxygen demand.
- This direct vasodilation contributes to, but is not the sole or primary reason, for symptom improvement in stable angina.
*Delayed electrical conduction*
- Nitroglycerin does **not significantly affect cardiac electrical conduction** or heart rate at therapeutic doses.
- Changes in conduction are typically managed by other antiarrhythmic medications.
*Increased atherosclerotic plaque stability*
- Nitroglycerin does **not stabilize atherosclerotic plaques**; it provides symptomatic relief by altering hemodynamic forces.
- Plaque stabilization is a long-term effect achieved through medications like statins and antiplatelet agents.
*Decreased venous pooling*
- Nitroglycerin actually **increases venous pooling**, which leads to a reduction in venous return to the heart (preload).
- It is this increased venous pooling and consequent reduction in preload that helps alleviate angina, not a decrease in venous pooling.
Question 918: A 55-year-old male is started on nitrate therapy for treatment of stable angina. He experiences significant and immediate relief of his symptoms within minutes of starting therapy. Approximately 48 hours after initiating this new medication, he notes return of chest pain and pressure with exertion that no longer responds to continued nitrate use. Which of the following 24-hour dosing schedules would most likely explain this patient's response to nitrate treatment?
A. PO regular-release isosorbide dinitrate taken at 8AM, noon, and 5PM
B. Transdermal nitroglycerin patch placed upon awakening in the morning and removed at 7PM without replacement
C. Transdermal nitroglycerin patch placed at 7AM then removed and replaced with another at 7PM (Correct Answer)
D. Transdermal nitroglycerin patch placed at bedtime and removed at 7AM without replacement
E. PO extended release isosorbide-5-mononitrate once daily at 8AM
Explanation: ***Transdermal nitroglycerin patch placed at 7AM then removed and replaced with another at 7PM***
- This dosing schedule provides **continuous 24-hour nitrate exposure** with no nitrate-free interval, which leads to rapid development of **nitrate tolerance** within 48 hours.
- The patient experiences immediate relief initially, but by replacing one patch with another at 7PM, there is **no washout period**, causing complete loss of efficacy.
- To prevent tolerance, an **off-nitrate period of 10-14 hours daily** is essential to restore nitrate responsiveness.
*PO regular-release isosorbide dinitrate taken at 8AM, noon, and 5PM*
- This schedule provides **intermittent nitrate exposure** with a nitrate-free interval overnight (approximately 15 hours from 5PM to 8AM).
- This built-in washout period would **prevent rapid tolerance development** and maintain drug efficacy.
*Transdermal nitroglycerin patch placed upon awakening in the morning and removed at 7PM without replacement*
- This is the **recommended dosing strategy** that provides a 12-14 hour nitrate-free interval overnight.
- This schedule would **prevent tolerance** and maintain therapeutic efficacy, unlike what occurred in this patient.
*Transdermal nitroglycerin patch placed at bedtime and removed at 7AM without replacement*
- This schedule provides a **nitrate-free window during daytime hours**, which would prevent tolerance development.
- The rapid loss of efficacy in this patient indicates a schedule with **continuous nitrate presence**, not this regimen.
*PO extended release isosorbide-5-mononitrate once daily at 8AM*
- Extended-release mononitrate taken once daily typically provides coverage for **12-17 hours**, not full 24-hour exposure.
- While this could theoretically contribute to tolerance with prolonged use, it would not explain the **rapid tolerance within 48 hours** as definitively as continuous transdermal patching without any removal period.
Question 919: A 51-year-old male presents to his primary care provider for a normal check-up. He reports that he “hasn’t felt like himself” recently. He describes feeling down for the past 8 months since his mother passed away. He has had trouble sleeping and has unintentionally lost 15 pounds. He feels guilty about his mother’s death but cannot articulate why. His performance at work has declined and he has stopped running, an activity he used to enjoy. He has not thought about hurting himself or others. Of note, he also complains of numbness in his feet and fingers and inability to maintain an erection. His past medical history is notable for diabetes. He is on metformin. His temperature is 98.6°F (37°C), blood pressure is 125/65 mmHg, pulse is 90/min, and respirations are 16/min. On exam, he is alert and oriented with intact memory and normal speech. He appears tired with a somewhat flattened affect. The best medication for this patient inhibits which of the following processes?
A. Amine degradation
B. Norepinephrine and dopamine reuptake
C. Norepinephrine and serotonin reuptake (Correct Answer)
D. Serotonin reuptake only
E. Dopamine receptor activation
Explanation: ***Norepinephrine and serotonin reuptake***
- This patient presents with symptoms highly suggestive of **major depressive disorder**, including persistent sadness, anhedonia, sleep disturbance, weight loss, and guilt, lasting for 8 months.
- Given his concurrent **diabetic neuropathy** (numbness in feet and fingers) and erectile dysfunction, a medication that targets both depression and neuropathic pain, such as a **Serotonin-Norepinephrine Reuptake Inhibitor (SNRI)** like **duloxetine**, would be the most appropriate choice, as SNRIs block the reuptake of both norepinephrine and serotonin.
*Amine degradation*
- Inhibiting amine degradation is the mechanism of action for **MAO inhibitors (MAOIs)**, which are effective antidepressants but are typically reserved for **refractory depression** due to their significant drug-drug and drug-food interactions (e.g., tyramine crisis).
- They are not considered first-line for a patient who can benefit from an SNRI, especially given the comorbid neuropathy.
*Norepinephrine and dopamine reuptake*
- This describes the mechanism of action of **bupropion**, an antidepressant that can be useful for **atypical depression** or in patients with concerns about sexual side effects.
- However, bupropion does not typically help with **neuropathic pain**, a significant co-morbidity in this patient.
*Serotonin reuptake only*
- This describes the mechanism of action of **Selective Serotonin Reuptake Inhibitors (SSRIs)**, which are often first-line for depression due to their generally favorable side effect profile.
- While effective for depression, SSRIs are generally **not effective for neuropathic pain** and may even worsen erectile dysfunction, making an SNRI a more suitable choice given the patient's full clinical picture.
*Dopamine receptor activation*
- **Dopamine receptor activators** (agonists) are primarily used in conditions like **Parkinson's disease** or for **restless legs syndrome**.
- They are not considered a primary treatment for major depressive disorder, nor do they address neuropathic pain.
Question 920: Ten days after starting a new medication, a 60-year-old man is brought to the emergency department after a 3-minute episode of myoclonic jerking movements and urinary incontinence. After regaining consciousness, the patient had no recollection of what happened and seemed confused. He has bipolar disorder, which has been controlled with maintenance therapy for the past 15 years. Physical examination shows dry oral mucosa, muscle fasciculations, and bilateral hand tremors. His speech is slow, and he is disoriented. Which of the following drugs most likely precipitated this patient's current condition?
A. Valproic acid
B. Celecoxib (Correct Answer)
C. Metoprolol
D. Theophylline
E. Fluoxetine
Explanation: ***Celecoxib***
- This patient's presentation of **myoclonic jerking, seizure, confusion, dry mucosa, fasciculations, and tremors** is classic for **lithium toxicity**.
- The patient has been on **maintenance therapy for bipolar disorder for 15 years**, most likely lithium, which has a narrow therapeutic index.
- **Celecoxib (COX-2 inhibitor/NSAID)** reduces renal clearance of lithium by decreasing renal prostaglandin synthesis, leading to **increased lithium levels and toxicity**.
- NSAIDs are a well-known precipitant of lithium toxicity in patients on chronic lithium therapy.
*Theophylline*
- Theophylline has a narrow therapeutic index and can cause seizures in toxicity, but this patient's presentation is consistent with **lithium toxicity**, not theophylline toxicity.
- Importantly, **theophylline actually decreases lithium levels** by increasing renal clearance, so it would not precipitate lithium toxicity.
- Theophylline toxicity typically presents with tachycardia and cardiac arrhythmias, which are not described here.
*Valproic acid*
- Valproic acid is used for bipolar disorder and can cause tremor and neurological side effects, but would not precipitate the acute toxicity syndrome seen here.
- Valproic acid toxicity typically involves **hepatotoxicity, pancreatitis, or CNS depression** rather than the hyperexcitable state with fasciculations and myoclonus.
- It does not interact significantly with lithium to cause this presentation.
*Metoprolol*
- Metoprolol is a **beta-blocker** that does not interact with lithium in a clinically significant way.
- Beta-blocker overdose causes **bradycardia, hypotension, and CNS depression**, not the hyperexcitable state with myoclonic jerks and fasciculations seen here.
*Fluoxetine*
- Fluoxetine is an **SSRI** that can increase lithium levels slightly, but is less commonly associated with precipitating lithium toxicity compared to NSAIDs.
- Severe SSRI toxicity or **serotonin syndrome** would present with **hyperthermia, hyperreflexia, clonus, and autonomic instability**, not the specific constellation of dry mucosa and fasciculations characteristic of lithium toxicity.
- The clinical picture better fits lithium toxicity precipitated by an NSAID.